Xenetic Biosciences, Inc. XBIO
1.84 USD +0.04 (+2.36%)
Nov 10, 2026, 2:36 PM EST
1.69 Day range 1.90
1.58 52-week range 4.94
- YTD
- -15.21%
- 1 year
- -30.57%
News
benzinga.com Xenetic Biosciences Announces Its Collaboration Partner PeriNess Doses First Participant In Clinical Trial Of Systemic Recombinant Human DNase To Treat Large B-Cell Lymphoma In Israel Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers,…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Apimeds Pharmaceuticals (AMEX:APUS) stock moved upwards by 76.7% to $5.69 during Monday's pre-market session. The market value of their outstanding shares is at $4.8 million. Alector…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Jaguar Health (NASDAQ:JAGX) stock increased by 304.5% to $10.8 during Tuesday's regular session. The company's market cap stands at $1.1 million. Greenland Mines (NASDAQ:GRML) shares moved…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers DataMEDS AI (NASDAQ:MEDS) shares increased by 354.9% to $7.37 during Wednesday's regular session. The company's market cap stands at $4.9 million. Q/C Technologies (NASDAQ:QCLS) shares…
benzinga.com Crude Oil Down Over 3%; US Business Inventories Surge In July U.S. stocks mixed: Dow slipped 0.1%, Nasdaq rose 0.7%, S&P 0.3%; tech led gains, energy fell, while oil dropped 3.2%.
benzinga.com Micro Cap Xenetic Biosciences Expands Therapeutic Platform With Santersus Acquisition Xenetic Biosciences plans to acquire Santersus in an all-stock deal, forming Santersus Bio to tackle NET-driven diseases.
benzinga.com Nasdaq Gains Over 100 Points; US Retail Sales Beat Estimates U.S. stocks edged higher as strong retail sales lifted sentiment; utilities gained, energy fell, oil dropped, while European and Asian markets advanced.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers DataMEDS AI (NASDAQ:MEDS) shares rose 124.1% to $3.63 during Wednesday's pre-market session. The company's market cap stands at $4.9 million. Tempest Therapeutics (NASDAQ:TPST) stock moved…
benzinga.com Xenetic Biosciences Q2 EPS $(0.41) Up From $(0.45) YoY, Sales $660.601K Up From $589.897K YoY Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.41) per share. This is a 8.89 percent increase over losses of $(0.45) per share from the same period last year. The company reported…- benzinga.com Xenetic Biosciences Announces That Its Collaboration Partner PeriNess Received Israeli Ministry Of Health Approval To Conduct An Exploratory Clinical Study Of Combination Systemic DNase I With Anti-CD19 CAR T Cells In Large B Cell Lymphoma Patients This approval follows positive preclinical results that demonstrated significant improvement of CAR T cell expansion and persistence and functionality when combined with DNase I. This combination…
- benzinga.com Xenetic Biosciences Reports ASCO 2026 Data Showing DNase I Boosts CAR-T Expansion And Anti-Tumor Activity In B-Cell Cancer Models New preclinical and translational findings position DNase I as a potentially transformative adjunct therapy for CAR-T treatment in aggressive B cell malignanciesData highlight potential of DNase I to…
benzinga.com Xenetic Biosciences Q1 EPS $(0.20) Up From $(0.59) YoY, Sales $806.923K Up From $593.261K YoY Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.20) per share. This is a 66.1 percent increase over losses of $(0.59) per share from the same period last year. The company reported…- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Xenetic Biosciences Q4 EPS $(0.22) Beats $(0.52) Estimate, Sales $766.296K Beat $690.000K Estimate Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.52) by 57.69 percent. This is a 67.65 percent increase over losses of…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Xenetic Biosciences Executes 4-Month Extension Of Collaboration With Institute Investigator At Scripps Research To Advance Development Of R&D Program Evaluating Combination Of Systemic Dnase I And CAR T-Cell Therapies Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers,…
benzinga.com Xenetic Biosciences Q3 EPS $(0.33) Beats $(0.49) Estimate, Sales $1.027M Beat $630.000K Estimate Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.49) by 32.65 percent. This is a 17.86 percent decrease over losses of…
benzinga.com Micron, Galecto And Xenetic Lead This Week's Benzinga Stock Ranking Surges Benzinga Edge Stock Rankings evaluate companies across four key factors. Here are three big companies that stood out this week.- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Xenetic Biosciences Prices Offering Of 735K Common Shares At $6.12/Shr For Gross Proceeds Of ~$4.5M Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers,…
benzinga.com 4 Stocks In The Same Sector Just Made A Huge Leap In Momentum Rankings Healthcare and biotech stocks have lagged broader markets this year, but a growing number of names have been picking up steam as the market rally broadens and major indexes continue to reach new…
benzinga.com Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket 
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Nasdaq Gains 150 Points; US Mortgage Applications Decline - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Why Confluent Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket 
benzinga.com Xenetic Biosciences Q2 EPS $(0.45) Beats $(0.65) Estimate, Sales $589.897K Miss $720.000K Estimate Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.65) by 30.77 percent. This is a 45.78 percent increase over losses of…- benzinga.com Xenetic Biosciences Announces First Patient Dosing In Exploratory Clinical Study Of Systemic DNase I In Combination With FOLFIRINOX For Advanced Or Metastatic Pancreatic Cancer Investigator initiated exploratory clinical study being conducted in Israel pursuant to agreement with collaboration partner, PeriNessCompany evaluating systemic recombinant human DNase I (DNase I)…
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com Xenetic Biosciences Q1 EPS $(0.59) Beats $(0.72) Estimate, Sales $593.26K Miss $670.00K Estimate Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0.72) by 18.06 percent. This is a 24.36 percent increase over losses of…
benzinga.com HC Wainwright & Co. Reiterates Neutral on Xenetic Biosciencesto Neutral HC Wainwright & Co. analyst Joseph Pantginis reiterates Xenetic Biosciences (NASDAQ:XBIO) from Neutral to Neutral.- benzinga.com HC Wainwright & Co. Reiterates Neutral on Xenetic Biosciencesto Neutral HC Wainwright & Co. analyst Joseph Pantginis reiterates Xenetic Biosciences (NASDAQ:XBIO) from Neutral to Neutral.
- benzinga.com Xenetic Biosciences Q4 EPS $(0.68) Misses $(0.20) Estimate, Sales $648.82K Beat $230.00K Estimate Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.20) by 240 percent. This is a 188.31 percent decrease over earnings…
- benzinga.com Xenetic Biosciences Net Loss For The Year Ended December 31, 2024 Was ~$4M; Ended The Year With ~$6.2M Of Cash Summary of Financial Results for Fiscal Year 2024Net loss for the year ended December 31, 2024 was approximately $4.0 million. Research and development expenses for the year ended December 31, 2024…
- benzinga.com HC Wainwright & Co. Reiterates Neutral on Xenetic Biosciencesto Neutral HC Wainwright & Co. analyst Joseph Pantginis reiterates Xenetic Biosciences (NASDAQ:XBIO) from Neutral to Neutral.
- benzinga.com Xenetic Biosciences Q3 EPS $(0.28) Misses $(0.20) Estimate, Sales $614.24K Beat $230.00K Estimate Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.20) by 40 percent. This is a 59.42 percent increase over losses of…
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash.
- benzinga.com Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Intervention U.S. Attorney General Merrick Garland said that the Justice Department would file an appeal with the U.S. Supreme Court seeking to block the entirety of Kacsmaryk's order suspending the FDA approval…
- benzinga.com Women's Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rules A U.S. federal appeals court has temporarily blocked a decision by a Texas judge to halt the FDA's approval of a widely used abortion drug.
- benzinga.com New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this…
- benzinga.com Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating…
- benzinga.com US Judge Weighs Nationwide Ban On Abortion Pills U.S. District Judge Matthew Kacsmaryk questioned President Joe Biden's administration lawyers on whether the federal regulatory approval of the abortion pill mifepristone was proper. The judge is…
- benzinga.com FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug'
- benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday's trading, 293 companies set new 52-week lows.
- benzinga.com Why Target Shares Are Trading Lower By 14%? Here Are 56 Stocks Moving In Wednesday's Mid-Day Session Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares jumped 109% to $0.2115 after dipping around 48% on Tuesday. Fast Radius established a timeline for a Chapter 11 sale process.
- benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday, 125 stocks hit new 52-week lows.